针对业绩短期波动，力诺药包管理层坦言，当前正处转型升级的"阵痛期"，其背后是前瞻性的战略投入。上市后，该公司 战略重心转向技术门槛更高的医药包装领域，持续加大对中硼硅模制瓶、预灌封注射器等高壁垒产品的资本投入。由于医药包 材行业认证周期长，新增产能效益释放需要时间，但随着产能逐步释放与市场开拓推进，盈利状况有望恢复。同时，公司在研 发创新与人才储备上保持持续高投入，以确保技术领先性。此外，2023年发行的可转债每年带来超2000万元财务费用增量，短 期内挤压利润，但公司视其为支撑转型的必要成本，展现出与客户共度行业调整期的韧性。 对于股东减持，该公司亦作出说明：复星系股东因基金存续周期与赎回压力实施减持，属于正常有序的市场化退出，目前 减持已到期；员工持股平台减持则因存续期已超十年，为满足部分在职、离职及退休员工的合理资金需求，体现了早期股权激 励机制的落实和对员工福祉的关切。力诺药包方面指出，核心管理层未参与减持，传递了经营团队与公司长期发展深度绑定的 信心。 本报讯 （记者王僖）近日，针对市场关注的管理层调整、业绩波动与股东减持等问题，山东力诺医药包装股份有限公司 （以下简称"力诺药包"）通过多渠道与市场 ...

对于短期业绩压力，公司表示这是转型升级中的"阵痛期"，公司自上市后，战略重心明确锁定在技术门 槛更高的医药包装领域，特别是中硼硅模制瓶、预灌封注射器、RTU等代表行业未来发展方向的创新型 产品。这类大规模、方向清晰的资本投入，是提升公司核心竞争力、布局长远的关键举措。对于新增产 能效益释放周期较长的问题，公司指出这主要源于医药包材行业严格的监管与客户认证流程，随着产能 的逐步释放以及下游市场开拓的逐步达成，盈利状况将得到恢复。 公司持续强化研发与人才储备，在市场拓展和研发创新方面的持续高投入，是公司确保技术领先性和未 来增长动能的直接努力。即使在财务压力下，公司仍坚持投入，显示了其以创新驱动发展的坚定信念。 据了解，力诺药包近期的人员变动是综合考虑个人意愿、岗位职能变化及治理结构完善的主动调整。尤 其是为顺应新《公司法》等法规要求，公司在调整董事会结构时，不仅完成了程序上的优化，更重要的 是将原具有丰富履职经验的监事及职工代表转为董事，强化了公司治理中的制衡机制与内部监督。此 外，原副总经理转赴海外专注重点项目建设，也是公司资源向战略性项目精准配置的体现。 团队年轻化与专业化是现代化公司团队管理的重要方向，本 ...

Group 1 - The company, Quzhou Dongfeng, announced that its sixth board meeting was held on December 25, 2025, via telecommunication to discuss changes in registered capital and amendments to the company’s articles of association [1] - For the first half of 2025, the revenue composition of Quzhou Dongfeng was as follows: pharmaceutical packaging accounted for 41.31%, membrane new materials for 34.19%, paper products for 14.47%, other businesses for 6.53%, and other categories for 3.06% [1] - As of the report date, Quzhou Dongfeng's market capitalization was 8.2 billion yuan [1]

12月23日，华兰股份涨1.26%，成交额2.08亿元。两融数据显示，当日华兰股份获融资买入额4930.55万 元，融资偿还6057.16万元，融资净买入-1126.62万元。截至12月23日，华兰股份融资融券余额合计5.45 亿元。 融资方面，华兰股份当日融资买入4930.55万元。当前融资余额5.45亿元，占流通市值的6.64%，融资余 额超过近一年90%分位水平，处于高位。 资料显示，江苏华兰药用新材料股份有限公司位于江苏省江阴市临港新城申港镇澄路1488号，成立日期 1992年6月4日，上市日期2021年11月1日，公司主营业务涉及直接接触注射剂类药品包装材料的研发、 生产和销售。主营业务收入构成为：覆膜胶塞49.07%，常规胶塞48.50%，其他2.43%。 截至9月30日，华兰股份股东户数1.33万，较上期减少13.09%；人均流通股11820股，较上期增加 49.59%。2025年1月-9月，华兰股份实现营业收入4.41亿元，同比增长4.36%；归母净利润5331.60万元， 同比增长2.06%。 分红方面，华兰股份A股上市后累计派现2.38亿元。近三年，累计派现1.44亿元。 责任编辑：小浪快 ...

（文章来源：证券日报） 证券日报网讯 12月23日，山东药玻发布公告称，公司将于2026年1月8日召开2026年第一次临时股东 会。 ...

每经AI快讯，海顺新材（SZ 300501，收盘价：15.91元）12月4日晚间发布公告称，近日接到公司控股 股东之一林武辉的通知，获悉林武辉将其所持有公司的部分股份办理了质押及解除质押手续。截至本公 告日，林武辉累计质押股数为1300万股，占其所持股份比例为21.82%。 （记者 张明双） 2025年1至6月份，海顺新材的营业收入构成为：医药包装新材料占比88.67%，其他占比10.31%，其他 业务占比1.02%。 每经头条（nbdtoutiao）——让"铁疙瘩"从数万米高空精准"踩刹车"，中国商业航天"降本复用"只差"最 后一公里"！朱雀之后，同行排队接力 截至发稿，海顺新材市值为31亿元。 ...

Core Viewpoint - The event organized by the China Listed Companies Association aims to enhance the governance level of listed companies and promote healthy development in the capital market through recognizing advanced practices in board operations and corporate governance [2] Group 1: Company Governance - The selection reflects the capital market's high recognition of the company's board governance capabilities and performance [2] - The company aims to strengthen governance and compliance, positioning investor relations management at a strategic level [2] Group 2: Strategic Vision - The company is leveraging the "14th Five-Year Plan" to align with its strategic vision of becoming a globally trusted pharmaceutical packaging enterprise [2] - The company plans to enhance shareholder returns through diversified methods, contributing to the high-quality development of the capital market [2]

Group 1 - The core viewpoint of the article highlights that Linuo Pharmaceutical Packaging (301188.SZ) has been recognized again for its exemplary practices in corporate governance and board operations by the China Association of Public Companies [1][3] - The evaluation activities were organized by the China Association of Public Companies, focusing on strategic leadership, investor relations management, internal control systems, and ESG principles to promote advanced experiences in board operations and corporate governance [3] - The recognition reflects the capital market's high regard for the company's board governance capabilities and performance, aligning with its strategic vision to become a trusted global pharmaceutical packaging enterprise [3] Group 2 - Linuo Pharmaceutical Packaging aims to enhance corporate governance and compliance, placing investor relations management at a strategic level to improve shareholder returns through diversified approaches [3] - The company intends to contribute to the high-quality development of the capital market by injecting strong momentum from the pharmaceutical packaging industry through superior governance and operational performance [3]

Core Viewpoint - The company and its wholly-owned subsidiary plan to establish a partnership to invest in high-potential sectors, particularly in new materials and Class I pharmaceutical packaging [1] Group 1: Investment Details - The company will contribute 980 million yuan, representing 49% of the total capital commitment for the new partnership [1] - The partnership aims to optimize the company's layout in specific industries and seek quality investment targets [1] Group 2: Strategic Objectives - The establishment of the partnership is intended to strengthen the company's industrial foundation and explore synergistic value [1] - The partnership will serve as a platform for investing in technology-driven enterprises and those with significant market development potential [1]

Core Viewpoint - The company, along with its wholly-owned subsidiary, plans to establish a partnership for investment in new materials and pharmaceutical packaging sectors, indicating a strategic move to enhance its industrial foundation and explore synergistic value [1] Group 1: Investment Details - The company will contribute 980 million yuan, representing 49% of the total capital commitment for the new partnership, named "衢州智峰" [1] - The partnership is formed with an entity that is indirectly controlled by the company's major shareholder, thus qualifying as a related party transaction [1] Group 2: Strategic Objectives - The establishment of the partnership aims to optimize the company's layout in new materials and Class I pharmaceutical packaging [1] - The partnership will serve as a platform for investing in technology-driven enterprises and those with significant market development potential [1]